NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) — The Combined General Meeting of Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS) was held on Tuesday, June 28, 2022 in Paris, at the Company’s headquarters. At the end of the Combined General Meeting, during which 67.23% of the voting rights were cast, resolutions 1 to 23 and 25 were adopted and resolutions 24 and 26 were rejected.
The detailed results of the vote can be viewed on the Company’s website:
https://www.cellectis.com/en/investor/general-meetings/
About Cellectis
Cellectis is a clinical-stage biotechnology company, which uses its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis is developing the first allogeneic immunotherapies therapeutic products based on CAR-T cells, inventing the concept of engineered off-the-shelf, ready-to-use CAR-T cells for the treatment of cancer patients, and a platform to realize therapeutic genetic modifications in hematopoietic stem cells in various diseases. By capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and the pioneering PulseAgile electroporation technology, Cellectis is developing innovative product candidates using the power of the immune system to treat it. illnesses with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis aims to develop UCART product candidates directed to the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, leukemia Acute B-cell lymphoblastic and multiple myeloma. HEAL is a new platform focused on hematopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases. Cellectis’ head office is located in Paris. Cellectis is also established in New York and Raleigh in the United States.
Cellectis is listed on the Euronext Growth market (code: ALCLS)
as well as on the Nasdaq Global Market (code: CLLS).
For more information, visit our website: www.cellectis.com
Follow Cellectis on social networks: @cellectis, LinkedIn and YouTube.
TALEN® is a registered trademark owned by Cellectis.
For more information, please contact:
Media contacts:
Pascalyne Wilson, Director, communications, 07 76 99 14 33, [email protected]
Investor relations contact:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, [email protected]
Sandya von der Weid, Associate Director, LifeSci Advisors, +41786800538
- Results shareholder’s meeting PR French.pdf
